Endocarditis in parenteral drug abusers. Right-sided endocarditis. Influence of HIV infection;Endocarditis en adictos a drogas por vía parenteral. Endocarditis derecha. Influencia de la situación VIH

Revista Espanola de Cardiologia

Volumn 51, Issue SUPPL. 2, 1998, Pages 71-78

  De Alarcón, Arístides ^a   Villanueva, José Luis ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

HIV infection; Parenteral drug abusers; Right sided endocarditis

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PROGNOSIS; REVIEW; RISK; RISK FACTOR; SUBSTANCE ABUSE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; ENDOCARDITIS, BACTERIAL; HIV INFECTIONS; HUMANS; MULTICENTER STUDIES; ODDS RATIO; PROGNOSIS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0031608725     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Gatell JM, Sasal M, Miró JM, Mensa J, Zamora L, García J. Endocarditis tricuspídea en los heroinómanos. Med Clin (Barc) 1981; 76: 303-306.
2. Force L, Verdaguer A, García A, Barrufet P, Molina L, Drobnic L. Endocarditis infecciosa en adictos. Presentación de 21 casos. Rev Clin Esp 1985; 175: 221-226.
3. Bernal JM, Molina L, González I, Nolla J, Garcés JM, Cerón A. Tratamiento medicoquirúrgico de la endocarditis infecciosa en pacientes heroinómanes. Rev Esp Cardiol 1986; 39: 283-288.
4. Camí J, Álvarez F, Monteis J, Caus J, Menoyo E, De Torres S. Heroína: nueva causa de urgencias toxicológicas. Med Clin (Barc) 1984; 82: 1-4.
5. Vergara de Campos A, Pérez-Moreno JM, Bichara G, Rodríguez-Gómez C, Freire-Macías JM, Peña-Santamaría L et al. Complicaciones médicas de 182 ingresos de heroinómanos en un hospital general. An Med Interna (Madrid) 1986; 15: (Supl 3): 20
6. Lahoz C, Mostaza JM, Valencia ME, Fernández J, Michán A, Suárez S. El adicto a drogas por vía parenteral en el servicio de urgencias. An Med Interna (Madrid) 1991; 8: 476-480.
7. Grupo de trabajo para el estudio de las infecciones en drogadictos. Estudio multicéntrico de las complicaciones infecciosas en adictos a drogas por vía parenteral en España: análisis de 11.645 casos (1977-1988). Enferm Infecc Microbiol Clin 1990; 8: 514-519.
8. Lacoste-Marín JA. ¿Está cambiando la vía de administración de heroína? Med Clin (Barc) 1992; 99: 517.
9. Torres-Tortosa M, Fernández-Elías M, Ugarte I, Ruiz López de Tejada M. Cambios en la vía de administración de droga en heroinómanos. Rev Clin Esp 1993; 193: 344-345.
10. Chan P, Ogilby JD, Segal B. Tricuspid valve endocarditis. Am Heart J 1989; 117: 1.140-1.146.
11. Louria DB, Mensle T, Rose J. The major medical complications of heroin addiction. Ann Intern Med 1967; 67: 1-22.
12. Cherubin CE, Baden M, Kavaler F. Infective endocarditis in narcotic addicts. Ann Intern Med 1968; 69: 1.091-1.098.
13. Gatell JM, Miró JM, Mensa J, Moreno MA, Mañá J, Segura F et al. Endocarditis infecciosa en drogadictos. Presentación de 25 casos procedentes del área de Barcelona. Med Clin (Barc) 1983; 80: 293-299.
14. Mesa JM, Oliver J, Domínguez F, Larrea JL, Cortina JM, Moreno I et al. Endocarditis infecciosa derecha. Experiencia de una serie de 35 pacientes. Rev Esp Cardiol 1990; 43: 13-17.
15. Ribera E, Martínez-Costa X, Tornos P, Gómez-Jiménez J, Planes A, Pahissa A et al. Endocarditis infeceiosa en drogadictos: estudio de 71 casos. Med Clin (Barc) 1990; 95: 5-9.
16. Torres Tortosa M, González Serrano M, Pérez Guzmán E, Vergara de Campos A, Pérez Jiménez J, Pérez Cortés S et al. Endocarditis infeceiosa en heroinómanos en la provincia de Cádiz. Un estudio multicéntrico sobre 150 episodios. Med Clin (Barc) 1992; 98: 521-526.
17. El-Khatib MR, Wilson FM, Lerner AM. Characteristics of bacterial endocarditis in heroin addicts in Detroit. Am J Med Sci 1976; 271: 197-201.
18. Hubbell G, Cheitlin MD, Rapaport E. Presentation, management and follow-up evaluation of infective endocarditis in drug addicts. Am Heart J 1981; 102: 85-94.
19. Levine DP, Crane LR, Zervos MJ. Bacteriemia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis 1986; 8: 374-396.
20. Shekar R, Rice TW, Zierdt CH, Kallick C. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype 011 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis 1985; 151: 203-208.
21. Watanakunakorn C. Changing epidemiology and newer aspects of infective endocarditis. Ann Intern Med 1977; 22: 21-47.
22. Tuazon CU, Hill R, Sheagren JN. Microbiologic study of street heroin and injection paraphernalia. J Infect Dis 1974; 129: 327-329.
23. Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus in narcotic addicts. J Infect Dis 1974; 129: 725-728.
24. Tuazon CU, Cardella TA, Sheagren JN. Staphylococcal endocarditis in drug users. Clinical and microbiological aspects. Arch Intern Med 1975; 135: 1.555-1.561.
25. Tuazon CU, Pérez A, Kishaba T, Sheagren J. Staphylococcus aureus among insulin infecting diabetic patients; an increased carrier rate. JAMA 1975; 231: 1.272.
26. Kirmani N, Tuazon CU, Murray HW, Parrish EA, Sheagren JN. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1.657-1.659.
27. Reisberg BE. Infective endocarditis in the narcotic addict. Prog Cardiovasc Dis 1979; 22: 193-204.
28. Sheagren JN. Endocarditis complicating parenteral drug abuse. En: Remington JS, Swartz MN, editores. Current clinical topics in infectious diseases. Nueva York: Mac Graw-Hill Book Company, 1981; 211-233.
29. Roberts WC, Buchbinder NA. Right-sided valvular infective endocarditis. A clinicopathologic study of twelve necropsy patients. Am J Med 1972; 53: 7-19.
30. Dressler FA, Roberts WC. Infective endocarditis in opiate addicts: analysis of 80 cases studied at necropsy. Am J Cardiol 1989; 63: 1.240-1.257.
31. Olsson RA, Romansky MJ. Staphylococcal tricuspid endocarditis in heroin addicts. Ann Intern Med 1962; 57: 755-762.
32. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia: current clinical patterns. Am J Med 1976; 60: 495-500.
33. a ed.). Nueva York: Churchill Livingstone Inc., 1990; 1.489-1.510.
34. Bayer AS, Theofilopoulos AN, Eisemberg R, Dixon FJ, Guze LB. Circulating immune complexes in infective endocarditis. N Engl J Med 1976; 295: 1.500-1.505.
35. Gutman RA, Striker GE, Gilliland BC, Cutler RE. The immune complex glomerulonephritis of bacterial endocarditis. Medicine (Baltimore) 1973; 51: 1-25.
36. Lowenstein MB, Urman JD, Abeles M, Weinstein A. Skin immunofluorescence in infective endocarditis. JAMA 1977; 238: 1.163-1.167.
37. Samet JF, Shevitz A, Fowle J, Singer DE. Hospitalization decision in febrile intravenous drug users. Am J Med 1990; 89: 53-57.
38. Weisse AB, Heller DR, Schimenti RJ, Montgomery RL, Kapila R. The febrile parenteral drug user: a prospective study in 121 patients. Am J Med 1993; 94: 274-280.
39. Irani WN, Grayburn PA, Afridi I. A negative transthoracic echocardiogram obviates the need for transesophageal echocardiograpy in patients with suspected native valve active infective endocarditis. Am J Cardiol 1996; 78: 101-103.
40. Karchmer AW. Antibiotic therapy of nonenterococcal streptococcal and staphylococcal endocarditis: current regimens and some future considerations. J Antimicrob Chemother 1988; 21 (Supl C): 91-103.
41. Bisno AL, Dismukes WE, Durack DT, Kaplan EL, Kerchmer AW, Kaye D et al. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA 1989; 261: 1.471-1.477.
42. Karchmer AW. Staphylococcal endocarditis. Am J Med 1985; 78 (Supl 6B): 116-127.
43. Myers JP, Linneman CC Jr. Bacteriemia due to methicillin-resistant Staphylococcus aureus. J Infect Dis 1982; 145: 532-536.
44. Levine DP, Cushing RD, Jui J, Brown WJ. Community acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97: 330-338.
45. Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to β-lactam antibiotics in vivo and in vitro. J Infect Dis 1984; 149: 894-903.
46. Craven DE, Kollish NR, Hsieh CR, Connolly MG Jr, McCabe WR. Vancomycin treatment of bacteriemia caused by oxacillin-resistant Staphylococcus aureus: comparison with β-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis 1983; 147: 137-143.
47. Gilbert DN, Wood CA, Kimbrough RC, and the Infecious Diseases Consortium of Oregon. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
48. Ryback MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, Thomson GA et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35: 696-700.
49. Wilson APR, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 1996; 38: 507-521.
50. Miller MH, Wexler MA, Steigbigel NH. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother 1978; 14: 336-343.
51. Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975; 131:367-375.
52. Sande MA, Courtney KB. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Clin Lab Med 1976: 88: 118-124.
53. Watanakunakorn C, Baird IM. Pronostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977; 273: 133-139.
54. Abrams B, Sklaver A, Hoffman T, Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979; 90: 789-791.
55. Karchmer AW. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med 1985; 78 (Supl 6B): 116-127.
56. Parker RH, Fossieck BE. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. Ann Intern Med 1980; 93: 832-834.
57. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109: 619-624.
58. Espinosa FJ, Valdés M, Martín-Luengo M, Arribas JP, Albadalejo J, Pérez-García A et al. Right endocarditis caused by Staphylococcus aureus in parenteral drug addicts: evaluation of a combined therapeutic scheme for two weeks versus conventional treatment. Enferm Infecc Microbiol Clin 1993; 11: 235-240.
59. Torres-Tortosa M, De Cueto M, Vergara A, Sánchez-Porto A, Pérez-Guzmán E, González-Serrano M et al, and Grupo de Estudio de Enfermedades Infecciosas de la provincia de Cádiz. Eur J Clin Microbiol Infect Dis 1994; 13: 559-564.
60. Ribera E, Gómez-Jiménez J, Cortés E, Del Valle O, Planes A, González-Alujas MT et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125: 969-974.
61. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob agentes Chemother 1990; 34: 1.227-1.231.
62. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-680.
63. Kaatz GW, Barriere SL, Schaberg DR, Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1987; 31: 527-530.
64. Fernández-Guerrero M, Rouse M, Henry N, Wilson W. Ciprofloxacin therapy of experimental endocarditis caused by methicillinsusceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 747-751.
65. Kaatz GW, Seo SM, Barriere LM, Rybak MJ. Ciprofloxacin and rifampicin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989; 33: 1.184-1.187.
66. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; 2: 1.071-1.073.
67. Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluorquinolones in staphylococci: an alert. Ann Intern Med 1991; 114:424-426.
68. Gómez-Jiménez J, Ribera E, Almirante B, Del Valle O, Pahissa A, Martínez-Vazquez JM. Ciprofloxacin resistance and staphylococcal endocarditis. Lancet 1989; 2: 1.525-1.526.
69. Tebas P, Martínez-Ruiz R, Román F, Mendoza P, Rodríguez-Díaz JC, Daza R et al. Early resistance to rifampicin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis 1991; 163: 204-205.
70. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101: 68-76.
71. Arbulu A, Thorns NW, Chiscano A, Wilson RF. Total tricuspid valvulectomy without replacement in the treatment of Pseudomonas endocarditis. Surg Forum 1971; 22: 162-164.
72. Arbulu A, Asfaw I. Tricuspid valvulectomy without prosthetic replacement. Ten years of clinical experience. J Thorac Cardiovasc Surg 1981; 82: 684-691.
73. Barbour DJ, Roberts WC. Valve excision only versus valve excision plus replacement for active infective endocarditis involving the tricuspid valve. Am J Cardiol 1986; 57: 475-478.
74. Alsip SG, Blackstone EH, Kirklin JW, Cobbs CG. Indications for cardiac surgery in patients with active infective endocarditis. Am J Med 1985; 78: 138-148.
75. DiNubile M. Surgery for addiction-related valve endocarditis: caveat emptor. Am J Med 1987; 82: 811-813.
76. Gintzon LE, Siegel RJ, Criley JM. Natural history of tricuspid valve endocarditis: a two dimensional echocardiographic study. Am J Cardiol 1982; 49: 1.853-1.859.
77. Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A. Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 1986; 80: 165-171.
78. Robbins MJ, Frater RW, Soeiro R, Frishman WH, Strom JA. Influence of vegetation size on clinical outcome of right-sided infective endocarditis. Am J Med 1986; 80: 165-171.
79. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Pronostic features in 102 episodes. Amn Intern Med 1992; 117: 560-566.
80. Barbour DJ, Roberts WC. Valve excision only versus valve excision plus replacement for active endocarditis involving the tricuspid valve. Am J Cardiol 1986; 57: 475-478.
81. a ed.). Nueva York: McGraw-Hill, 1990; 885-862.
82. Valencia ME, Guinea J, Soriano V, Martínez ML, Moreno V, Laguna F et al. Estudio de 164 episodios de endocarditis infecciosa en drogadictos: comparación entre pacientes VIH positives y negativos. Rev Clin Esp 1994; 194: 535-539.
83. Nahass RG, Weinstein MP, Bartels J, Gocke DJ. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative patients and -positive patients. J Infect Dis 1990; 162: 967-970.
84. Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosupression. Clin Infect Dis 1996; 22: 40-45.
85. Centers for Disease Control. Classification system for human T-lymphotropic virus III/lymphadenopaty associated virus infection. MMWR 1986; 35: 334-339.
86. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical and immunologic prospectives. Ann Intern Med 1992; 117: 314-324.
87. Murphy PM, Lane HC, Fauci AS, Gallin JL. Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis 1988; 158: 627-630.
88. Pitrak DL, Bak PM, DeMarais P, Novak RM, Andersen BR. Depresesed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 1993; 167: 1.406-1.410.
89. Chaisson RE, Keruly J, Richman DD, Moore RD, the Zidovudine Epidemiology Group. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992; 152: 2.009-2.013.